

Suppression of inflammatory cytokines expression with bitter melon (*Momordica charantia*) in TNBS-instigated ulcerative colitis

Asli Semiz¹, Ozden Ozgun Acar², Hulya Cetin³, Gurkan Semiz⁴, Alaattin Sen^{4,5}

¹Pamukkale University, Faculty of Technology, Department of Biomedical Engineering, Denizli 20070, Turkey;

²Pamukkale University, Seed Breeding & Genetic Application and Research Centre Denizli 20070, Turkey;

³Pamukkale University, Faculty of Medicine, Basic Medical Sciences-Histology and Embryology, Denizli 20070, Turkey;

⁴Pamukkale University, Faculty of Arts and Sciences, Biology Department, 20070 Denizli, Turkey;

⁵Abdullah Gul University, Faculty of Life and Natural Sciences, Department of Molecular Biology and Genetics, 38080 Kayseri, Turkey

ABSTRACT

Background and Objective: This study was aimed to elucidate the molecular mechanism of *Momordica charantia* (*MCh*), along with a standard drug prednisolone, in a rat model of colitis induced by trinitrobenzene sulfonic acid (TNBS). **Methods:** After the induction of the experimental colitis, the animals were treated with *MCh* (4 g/kg/day) for 14 consecutive days by intragastric gavage. The colonic tissue expression levels of C-C motif chemokine ligand 17 (CCL-17), interleukin (IL)-1 β , IL-6, IL-23, interferon- γ (IFN- γ), nuclear factor kappa B (NF- κ B), and tumor necrosis factor- α (TNF- α), were determined at both mRNA and protein levels to estimate the effect of *MCh*. Besides, colonic specimens were analyzed histopathologically after staining with hematoxylin and eosin. **Results:** The body weights from TNBS-instigated colitis rats were found to be significantly lower than untreated animals. Also, the IFN- γ , IL-1 β , IL-6, IL-23, TNF- α , CCL-17, and NF- κ B mRNA and protein levels were increased significantly from 1.86-4.91-fold and 1.46-5.50-fold, respectively, in the TNBS-instigated colitis group as compared to the control. Both the *MCh* and prednisolone treatment significantly reduced the bodyweight loss. It also restored the induced colonic tissue levels of IL-1 β , IL-6, IFN- γ , and TNF- α to normal levels seen in untreated animals. These results were also supported with the histochemical staining of the colonic tissues from both control and treated animals. **Conclusion:** The presented data strongly suggests that *MCh* has the anti-inflammatory effect that might be modulated through vitamin D metabolism. It is the right candidate for the treatment of UC as an alternative and complementary therapeutics.

Key words: *Momordica charantia*, ulcerative colitis, inflammatory bowel disease, anti-inflammatory, inflammatory cytokines, vitamin D, CYP27B1, trinitrobenzenesulfonic acid, immunohistochemistry, alternative and complementary therapeutics

Address for Correspondence:
Dr. Alaattin Sen, PhD, Abdullah Gul University, Faculty of Life and Natural Sciences, Department of Molecular Biology and Genetics, Sumer Campus, Kocasinan, 38080 Kayseri, Turkey
E-mail: sena@agu.edu.tr; sena@pau.edu.tr

Access this article online

Website:

www.intern-med.com

DOI:

10.2478/jtim-2020-0027

Quick Response Code:



INTRODUCTION

Inflammatory bowel diseases (IBD) are described by chronic relapsing inflammation in the gastrointestinal tract. They are generally divided into two main groups, Crohn's Disease (CD) and Ulcerative Colitis (UC).^[1] CD is a disease that can keep the entire digestive tract from mouth to anus in a segmental manner and transmurally,

followed by remission and exacerbations.^[2,3] On the other hand, UC is a chronic IBD that diffuses from the rectum to the proximal length without leaving any intact parts and diffuses the colon mucosa with remission and exacerbations.^[4] Although the etiology remains a mystery, the current view is inflammation caused by inflammatory cells and cytokines via a complex network of interactions.^[5]

Cytokines are essential molecules in the initiation and regulation of inflammatory immune responses. For normal colon homeostasis, anti-inflammatory [such as interleukin (IL)-4, IL-10, IL-11, and IL-13] and pro-inflammatory [such as IL-1, IL-2, IL-6, IL-8, IL-12, IL-23, tumor necrosis factor (TNF)- α , and interferon (IFN)- γ] cytokines in the colonic mucosa need to be in balance.^[6,7] UC disease is associated with the elevation of inflammatory markers such as IL-1 β , IL-6, TNF- α , and IFN- γ .^[8-12] Chemokines also play an essential role in the course of inflammation. A significant increase of some chemokines is observed in the intestinal tissues of patients with UC and CD.^[13] C-C motif chemokine ligand 17 (CCL-17) is a C-C motif chemokine that is expressed in the thymus and associated with the induction of chemotaxis in T cells.^[14] Nuclear factor kappa B (NF- κ B) is a nuclear transcription factor and plays a critical role in regulating multiple gene transcription associated with immunity and inflammation.^[15-18] It is recognized as one of the dominant players in the pathogenesis of UC.^[19]

The utilization of plants and plant-based preparations as complementary and alternative therapeutics has attained popularity throughout the world in recent decades.^[20] According to the World Health Organization, it is estimated that 80% of the population in developing countries rely on traditional medicinal plants.^[21] *Momordica charantia* (*MCh*) is one such plant used as traditional medicine for various ailments such as tumors, skin diseases, wounds, eczema, scabies, rheumatism, malaria, menstrual problems, diabetes, gastric ulcer, feverish conditions, and intestinal worms.^[17,21-30] In our country, *MCh* is widely used for the treatment of UC and peptic ulcer.^[31] This study was aimed to elucidate the molecular mechanism of *MCh* in a rat model of colitis instigated by TNBS.

MATERIALS AND METHODS

Plant material

The ripened (orange-yellow) fruits of *MCh* were purchased from local street markets in July 2017 and identified taxonomically by G. Semiz. *MCh* fruits are washed with tap water, stripped of water, chopped into small pieces (approximately 0.5 cm³ pieces) and placed in a 1 L glass jar. After addition of an equal amount of virgin olive oil, the jar was tightly closed and exposed to sunlight for six weeks. At the end of the incubation period, the resulting marmalade was homogenized by passing through the blender and kept at room temperature in a dark environment. The marmalade was prepared as used by local folks, without involving any chemicals.

Animals

Thirty-five healthy male Wistar rats (twelve-week old ranging 220–250 g body weights) were purchased from

the Pamukkale University Animal House. The animals were housed in small polypropylene cages with a 12-h light/12-h dark photocycle in a temperature-controlled room (22 \pm 1°C) and were fed commercial rat food with water *ad libitum*. Animal experiments were performed under appropriate ethical administration with veterinary services within licensed projects approved by the Institutional Experimental Animal Ethics Committee (PAUHDEK-2015/18). The animal protocol was intended to minimize pain or discomfort to the animals. Intra-gastric gavage administration was carried out with cognizant animals, utilizing straight gavage needles fitting for animal size.

Induction of colitis

Colonic inflammation was induced based on the method of El-Salhy^[32] with slight modifications. Thirty-five rats divided into five experimental groups as follows:

Group I-Normal control (NC) group: only received distilled water for 14 day.

Group II-Ulcerative colitis control (UCC) group: Anaesthetized rats were treated with rectal catheterization followed by 30 mg/0.1 mL TNBS and 0.5 mL 50% ethanol mixture to induce colitis formation. Animals are expected to be UC at the end of 7 day. At the end of this period, since *MCh* marmalade was prepared in olive oil, the rats were fed with olive oil by intragastric gavage for 14 d to see the solvent's effects. In other words, the goal of the UCC group was to control for olive oil effects in treatment with *MCh*.

Group III-Ulcerative colitis (UC) group: Anaesthetized rats were treated with rectal catheterization followed by 30 mg/0.1 mL TNBS and 0.5 mL 50% ethanol mixture to induce colitis formation. Animals are expected to be UC at the end of 7 day. This group of animals were kept untreated for a further duration of the experiment.

Group IV-*M. charantia* (*MCh*) group: Anaesthetized rats were treated with rectal catheterization followed by 30 mg/0.1 mL TNBS and 0.5 mL 50% ethanol mixture to induce colitis formation. Animals are expected to be UC at the end of 7 day. At the end of this period, rats were fed with 4 g/kg/day of *MCh* marmalade for 14 days by intragastric gavage. The dose given was determined by considering the dose used among the population.

Group V-Positive drug Prednisolone (PR) group: Anaesthetized rats were treated with rectal catheterization followed by 30 mg/0.1 mL TNBS and 0.5 mL 50% ethanol mixture to induce colitis formation. Standard drug prednisolone was given on the same day by oral gavage (2

mg/kg/day, 7 day). This group of animals were kept for the duration of the experiment.

After the last treatment or day, all rats were fasted overnight (16–18 h). Once the animals were sacrificed by cervical dislocation, the colons were removed aseptically and placed on ice-cold physiological saline. Colonic specimens were washed gently with physiological saline to remove fecal residues and then immediately frozen in liquid nitrogen. Blood samples to determine the serum enzymes were taken from the aorta. Portions of colonic tissue samples were fixed in 10% paraformaldehyde solution for histochemical studies.

Histopathological analysis

Histopathological analysis was carried out by a histopathologist from the Faculty of Medicine at Pamukkale University as described elsewhere.^[33] Basically, the colon samples were fixed in 10% formalin in phosphate buffer for 24 h, processed routinely for paraffin embedding, sectioned at 3–4 μ m, and stained with hematoxylin and eosin (H&E). Histological scoring was based on three parameters as described below: a) severity of inflammation: 0 = no inflammation; 1 = mild; 2 = moderate; 3 = severe; b) depth of inflammatory involvement: 0 = no inflammation; 1 = mucosa; 2 = mucosa and submucosa; 3 = transmural; c) crypt damage: 0 = intact crypts; 1 = loss of the basal one-third; 2 = loss of the basal two-thirds; 3 = entire crypt loss and change of epithelial surface with erosion.^[34] Five random fields were evaluated for each section.

Determination of serum AST and ALT and LDH activities

In order to evaluate the toxic potential of the *MCh* marmalade, levels of serum transaminases [Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)] and Lactate dehydrogenase (LDH) were determined using procedures based on the methods described.^[35,36] Blood samples were centrifuged for 10 min at 4000 r/min at 4°C to separate serum.

RNA isolation and cDNA synthesis

Total RNA was isolated from about 100 mg colonic samples with the RNeasy lipid tissue universal mini kit (Qiagen) according to the instructions provided by the manufacturer and as optimized in our laboratory.^[37] The extracted RNA was quantified by measuring the absorbance at 260/280 nm, and RNA integrity was analyzed by 1% agarose gel. RNA was reverse transcribed using a RevertAid Reverse Transcriptase (ABM).^[38]

RT-PCR of mRNAs

Semi-quantitative RT-PCR was carried out using gene-specific primers (Table 1). Beta-actin (ACTB) gene was

used to normalize gene expressions. The PCR amplification conditions were applied as described.^[20] The PCR products were detected on 1.5% agarose gels, and the bands were visualized using GelQuant Image Analysis Software in the DNR LightBIS Pro Image Analysis System. The relative intensity of the bands was reported relative to ACTB expression. All gene analyses were performed in triplicate and repeated at least three times.

Table 1: Primer sequences and amplification conditions

Gene	Primer Sequence (5' -> 3')	Annealing Temperature (°C)
IFN- γ	F→ GCCGCGTCTTGTTTTGCAG R→ TACCGTCCTTTTGCCAGTTCCTCCA	65
IL-1 β	F→ CATCAGCACCTCTCAAGCAGA R→ CATTCTCGACAAGGGGCTC	63
IL-6	F→ TCTCTCCGCAAGAGACTTC R→ TCTTGGTCCTTAGCCACTCC	60
IL-23	F→ AAAGGAGTTGATAGAGGGT R→ TCTTAGTAGATCCATTTGTCCC	57
TNF- α	F→ GCCAATGGCATGGATCTCAAAG R→ CAGAGCAATGACTCCAAAGT	59
CCL-17	F→ ACCTTCACCTCAGCTTTTGGTACCATG R→ GCGTCTCCAAATGCCTCAGCGGAAGG	68
NF- κ B	F→ ACCTGGAGCAAGCCATTAGC R→ CGGACCGCATTCAAGTCATA	55
ACTB	F→ TGCAGAAGGAGATTACTGCC R→ CGCAGCTCAGTAACAGTCC	65

Preparation of tissue homogenate

Colon samples were cut to small pieces and granulated in liquid nitrogen by mortar and pestle. Powdered colon samples were weighed (100 mg) into plastic tubes with 10% TCA (2,4,6-trichloroanisole) and 20 mmol/L DTT (dithiothreitol). The mixture was incubated on ice for 1 h and was centrifuged at 12,500 r/min for 20 min at 4°C. Finally, the pellet was dissolved in cold solubilization buffer [7 mol/L urea, 2 mol/L thiourea, 2% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate), protease inhibitor cocktail, and 2 mmol/L DTT]. The amounts of protein were measured with the Bicinchoninic acid (BCA) method using the bovine serum albumin (BSA) standard.^[39]

Gel electrophoresis and western blotting

SDS-PAGE and Western blotting analyses were carried out as described previously.^[40,41] Briefly, samples (80 μ g protein) were resolved on 8.5% polyacrylamide gel with a discontinuous buffer system of Laemmli.^[42] The dissociated proteins were transferred onto polyvinylidene difluoride (PVDF) membrane with the Hoefer blotting system (90 V, 90 min at 4°C). Following the transfer, the membranes were blocked with 5% non-fat dry milk in TBST [20 mmol/L Tris-HCl, pH 7.4, 400 mmol/L NaCl, and 0.1% (v/v) Tween 20] for 40 min. Blot was incubated sequentially with primary antibodies (1/1000)

and HRP-conjugated secondary antibodies (1/5000) in TBST containing 5% non-fat for 2 h and 1 h, respectively, while constant shaking at room temperature. Blot were then incubated with Pierce ECL western blotting substrate solution to detect immunoreactive proteins. The bands were visualized using GelQuant Image Analysis Software in the DNR LightBIS Pro Image Analysis System. The protein bands were quantified by measuring band density using Scion Image Version Beta 4.0.2 software.

Statistical analysis

All results were expressed as means, including their Standard Error of Means (SEMs). A comparison between groups was performed using Student's *t*-test, and $P < 0.05$ was selected as the level required for statistical significance. These statistical analyses were carried out using the Minitab 13 statistical software package.

RESULTS

During the treatment protocol, TNBS-instigated UC rats showed significant reductions in body weight compared to the NC group (Table 2). Nevertheless, both *MCh* and PR treated groups showed significant improvements in body weight loss. The effects of *MCh* on the serum transaminases and LDH in control and experimental colitis rats are given in Table 2. Significant differences were observed between the mean transaminases (ALT and AST) and LDH values of the control and UC groups. However, no differences were observed between control and *MCh*-treated rats

The paraffin sections of colonic specimens were subjected to H&E staining for the detection of ulceration and sign of colitis. It was observed that the H&E stained control group had healthy histological structure (Figure 1A). However, histopathological changes such as the presence of diffuse areas of inflammation and loss of cryptic structures in the UC and UCC groups as compared to the NC group (Figure 1B and 1C). Besides, it was found that there was a decrease in the areas of inflammatory cell infiltration in the treatment groups (*MCh* and PR treated) when compared with the UC and UCC groups as shown in Figure 1D and 1E. All treatment groups had significantly lower histological scores than that observed in the UC group (Figure 1F).

The effect of *MCh* marmalade on the mRNA levels of inflammatory cytokines/chemokines/transcription factors (such as IFN- γ , IL-1 β , IL-6, IL-23, TNF- α , CCL-17, and NF-kB) was also determined throughout in this study (Table 3). IFN- γ , IL-1 β , IL-6, IL-23, TNF- α , CCL-17, and NF-kB mRNA levels were increased significantly, from 1.38-2.23-fold, in the UC group compared to the control, as shown in Table 3. On the other hand, treatment with *MCh* reduced mRNA expressions significantly, from 2.12-

3.54-fold, concerning the UC rats (Table 3). Group V rats treated with the standard drug (PR) also shown decreased levels in IFN- γ , IL-1 β , IL-6, IL-23, TNF- α , CCL-17, and NF-kB, as shown in Table 3.

To determine the extent of the ameliorative effect of *MCh* marmalade at the protein level of the selected genes, proteins were initially resolved on polyacrylamide gels and then analyzed on immunoblots probed with different antibody preparations (Figure 2). The densitometric scanning of western blot results showed that the protein levels of inflammatory cytokines/chemokines/transcription factors (IFN- γ , IL-1 β , IL-6, IL-23, TNF- α , CCL-17, and NF-kB) were increased significantly, from 1.46-5.50-fold, in the UC group compared to the NC group (Table 4). On the contrary, treatment with *MCh* reduced protein levels of these cytokines/chemokines/transcription factors significantly, from 1.31-3.22-fold, concerning the UC rats (Table 4). Besides, the treatment with *MCh* and PR reduced the protein levels significantly compared with the UC group, as shown in Figure 2.

DISCUSSION

Genetic, environmental, and especially immunological factors are thought to play an essential role in the pathogenesis of ulcerative colitis. Therefore, drugs targeting immuno-inflammatory pathways have been used in the treatment of UC for the last 15 years. Although many new drugs have been developed for this purpose, aminosaliculates and corticosteroids are the most commonly used drugs in the treatment of UC. However, alternative plant-based therapies are also used by the public in the treatment of the disease. Plants have natural potentials to promote healing mechanism with fewer side effects.^[21,43] The simplicity of establishing experimental UC model in rats has enabled the investigation of various agents in the treatment of this disease. In our country, *M. charantia* is widely used in the treatment of peptic ulcer and UC.^[24,32]

In this study, molecular mechanisms of the potential therapeutic effect of *MCh* in TNBS-instigated colitis model were investigated. The most important and useful aspects of the TNBS-instigated colitis model is the similarity of inflammation to IBD.^[44,45] Moreover, the changes in body weight and weight loss in the TNBS-instigated colitis model are shown to arise as similar to human UC.^[46,47] In our study, it was observed that there was a significant decrease in mean body weight in the TNBS-instigated experimental UC group compared to the NC group in accordance with the literature. In addition, both *MCh* and PR treatment not only restored body weight loss but also causes a significant increase in body weight, which might be considered as a sign of recuperation (Table 2).




Figure 1: Histopathological images of colon tissues stained with H&E. (A) The appearance of normal colonic mucosa in the normal control group. (B and C) Inflamed ulcerative colitis mucosa in colitis control and colitis groups, associated with mucosal layer destruction, crypt damage and intense inflammatory cell infiltration in the mucosa and submucosa. Colitis tissue treated with (D) *MCh* (4 g/kg/day) and (E) PR (2 mg/kg/day) showing improved histopathological signs of colon damage including the decrease of infiltration areas in the lamina propria layer of mucosa and loss of crypts seen less than colitis group. (★: infiltration areas, ➔: loss of crypts). (F) Histopathological analysis showed tissue degradation. * $P < 0.001$ vs. the control group; * $P < 0.01$, ** $P < 0.001$ vs. the model group.

As shown in Table 2, blood serum AST, ALT and LDH activities were increased in the colitis group compared to the control rats. The elevated activities of these serum marker enzymes are indicative of loss of functional integrity in liver.^[48–50] The absence of any increase in the levels of these enzymes in the treatment groups implies that *MCh* does not pose any toxicity, particularly to tissues such as erythrocytes, heart muscle, liver and lungs.

Microscopic assessment of H&E stained sections showed healthy histological structure in the control group. The mucosal surface was covered with a single-layer prismatic epithelium containing multiple goblet cells. When H&E stained sections from UC and UCC groups were examined, histopathological changes, such as the presence of diffuse areas of inflammation and loss of cryptic structures, were detected as reported by different researchers.^[35,51–53] In addition, thinning of the mucosal layer, erosion and deterioration were observed in the surface epithelium covering the mucosa. However, when UC and UCC groups were compared with the treated with *MCh* and PR treated group, it was found that there was a decrease in the areas of inflammatory cell infiltration. The observed anti-inflammatory and healing effects of *M. charantia* may be attributed to hindering leukocyte infiltration and preventing edema as reported by other studies.^[54–56]

IL-6 produced in response to TNF and IL-1 is one of the crucial cytokines acting in the inflammatory response and cancer pathogenesis.^[57,58] It is known that IL-6 and IL-1 released by active macrophages are increased in UC, CD and experimental colitis models.^[59–62] Similarly, other studies have shown that levels of pro-inflammatory cytokines, such as TNF- α , IL-1 β , and IL-6, are elevated in IBD and are directly proportional to the severity of inflammation and levels of these cytokines.^[1,21,63,64] The present findings that the *MCh* treatment reduced IL-1 β and IL-6 mRNA and protein levels 2.10- and 2.90-fold and 2.62- and 2.78-




Figure 2: Quantification of proteins in rat colon tissues from various groups by western blot analysis. Rats were treated and proteins were extracted as described in Materials and Methods section. The proteins were separated by SDS-PAGE and western blot analysis was performed as described. Each lane contained 100 μ g protein. Proteins were detected using chemiluminescent substrate and bands were visualized and recorded using a DNR Light IS Pro Image Analysis System.

Table 2: Blood serum LDH, AST, and ALT enzyme activities in control, colitis, and treated rats

Groups	Enzyme Activities (U/L)			Body Weights (g)	
	LDH	AST	ALT	Begin	End
Normal control	608 \pm 96	36 \pm 08	30 \pm 6	236 \pm 30	235 \pm 30
UC control	1503 ^a \pm 125	82 ^a \pm 12	85 ^a \pm 13	226 \pm 7	221 \pm 11
UC	1516 ^{a,b} \pm 166	85 ^{a,b} \pm 15	85 ^a \pm 13	228 \pm 30	204 \pm 28 ^a
MCh-treated	610 ^{a,b} \pm 90	25 ^{a,b} \pm 02	23 ^{a,b} \pm 02	238 \pm 27	249 \pm 28 ^{a,b}
PR-treated	580 ^{a,b} \pm 67	37 ^{a,b} \pm 05	35 ^{a,b} \pm 07	257 \pm 17	266 \pm 24 ^{a,b}

^aSignificantly different from the respective control value $P < 0.05$

^bSignificantly different from the respective UC control value $P < 0.05$

fold, respectively, further support the anti-inflammatory action of *MCh*.

TNF- α is vital in the host's normal response to viral, bacterial and parasitic infections, but insufficient or overproduction is harmful to the host.^[65] In IBD, TNF- α act as the main constituent and increased colonic TNF- α expression in TNBS-instigated colitis model is well documented.^[18,21,63,66,67] Increased activation of innate and adaptive immune system cells in IBD causes increased cytokines of TNF- α , IL-1 β and IL-23/Th17 pathway.^[68] IL-23 is a member of a small family of pro-inflammatory cytokines and plays a vital role in the pathogenesis of many immune-mediated inflammatory diseases, including IBD.^[69-72] Numerous studies have shown that IL-23 is essential for the development of IBD.^[73-75] Significant reductions in levels of TNF- α , IFN- γ and IL-6 pro-inflammatory cytokines have been identified in IL-23 deficiency.^[72-74] The current study manifested that *MCh* treatment significantly reduced the TNBS-instigated TNF- α inductions in rats, which is a well-known and significant player of systemic inflammation.

Another cytokine, interferon-gamma (IFN- γ) secreted by Th1 lymphocytes, is involved in the pathogenesis of colitis.^[18,76,77] When intestinal epithelial cells are damaged, IFN- γ

aggregates in the damaged intestinal mucosa to participate in epithelial immune response.^[18,78] Anti-IFN- γ antibody treatment significantly reduced the damage in the TNBS-colitis model.^[79] In our study, colonic IL-1 β , IL-6, IL-23, TNF- α , and IFN- γ protein and mRNA expression levels were significantly higher in the colitis group compared to the control group in accordance with the literature. The treatment with *MCh* fruit marmalade has also optimally reduced the TNBS-induced levels of inflammatory mediators, IL-1 β , IL-6, IL-23, TNF- α , and IFN- γ , which are comparable to those achieved by the standard drug (PR) treatment.

In inflammation, blood chemokines lead to the passage of leukocytes into the tissue and accumulation and activation at the site of inflammation.^[80] CCL-17 is a C-C chemokine and expressed in the thymus.^[14] While CCL-17 shows upregulation in stress, injury or inflammation, overexpression is seen in autoimmune disorders including UC and CD.^[13,81,82] In human CCL-17 is induced by IFN- γ and TNF- α stimulation.^[13] CCL-17 was the highest increased gene (5.5-fold and 2.23-fold for protein and mRNA level, respectively) in our study and returned to almost control values with the *MCh* treatment.

Table 3. The expression level of the selected genes in the control, colitis, and treatment groups

Genes	NC	UCC	UC	NC vs. UC	MCh	PR	UC vs. MCh
IFN- γ	100 \pm 3	151 ^a \pm 4	151 ^a \pm 6	1.51x \uparrow	56.34 ^{a,b} \pm 5	56.1 ^{a,b} \pm 2	2.68x \downarrow
CCL-17	100 \pm 6	220 ^a \pm 4	223 ^{a,b} \pm 5	2.23x \uparrow	63.0 ^{a,b} \pm 4	60.0 ^{a,b} \pm 7	3.54x \downarrow
TNF- α	100 \pm 5	137 ^a \pm 6	141 ^{a,b} \pm 4	1.41x \uparrow	63.8 ^{a,b} \pm 7	65.1 ^{a,b} \pm 5	2.21x \downarrow
IL-23	100 \pm 3	134 ^a \pm 2	138 ^{a,b} \pm 5	1.38x \uparrow	65.6 ^{a,b} \pm 4	53.4 ^{a,b} \pm 7	2.12x \downarrow
IL-1 β	100 \pm 5	178 ^a \pm 8	183 ^{a,b} \pm 5	1.83x \uparrow	62.6 ^{a,b} \pm 7	56.5 ^{a,b} \pm 3	2.92x \downarrow
IL-6	100 \pm 2	151 ^a \pm 5	158 ^{a,b} \pm 4	1.58x \uparrow	75.2 ^{a,b} \pm 3	77.2 ^{a,b} \pm 6	2.10x \downarrow
NF-kB	100 \pm 3	169 ^a \pm 1	172 ^{a,b} \pm 4	1.72x \uparrow	61.8 ^{a,b} \pm 2	61.3 ^{a,b} \pm 2	2.78x \downarrow

NC: normal control; UCC: ulcerative colitis control; UC: ulcerative colitis; MCh: *M. charantia* treated; PR: prednisolone treated.

Control was taken as 100%

^aSignificantly different from the respective control value $P < 0.05$

^bSignificantly different from the respective UC control value $P < 0.05$

Table 4. Relative expressions of the selected genes at the protein level in the control, colitis and treatment groups

Proteins	NC	UCC	UC	NC vs. UC	MCh	PR	UC vs. MCh
IFN- γ	100 \pm 7	201 ^a \pm 9	198 ^{a,b} \pm 8	1.98x \uparrow	103 ^{a,b} \pm 5	97 ^{a,b} \pm 6	1.91x \downarrow
CCL-17	100 \pm 8	555 ^a \pm 11	549 ^{a,b} \pm 9	5.50x \uparrow	170 ^{a,b} \pm 6	117 ^{a,b} \pm 7	3.22x \downarrow
TNF- α	100 \pm 4	143 ^a \pm 9	146 ^{a,b} \pm 8	1.46x \uparrow	111 ^{a,b} \pm 7	107 ^{a,b} \pm 8	1.31x \downarrow
IL-23	100 \pm 8	221 ^a \pm 8	205 ^{a,b} \pm 10	2.05x \uparrow	118 ^{a,b} \pm 5	103 ^{a,b} \pm 7	1.74x \downarrow
IL-1 β	100 \pm 4	282 ^a \pm 8	317 ^{a,b} \pm 13	3.16x \uparrow	114 ^{a,b} \pm 7	159 ^{a,b} \pm 4	2.78x \downarrow
IL-6	100 \pm 5	227 ^a \pm 10	241 ^{a,b} \pm 5	2.40x \uparrow	92 ^{a,b} \pm 7	121 ^{a,b} \pm 8	2.62x \downarrow
NF-kB	100 \pm 6	257 ^a \pm 10	305 ^{a,b} \pm 6	3.06x \uparrow	186 ^{a,b} \pm 4	144 ^{a,b} \pm 9	1.64x \downarrow

NC: normal control; UCC: ulcerative colitis control; UC: ulcerative colitis; MCh: *M. charantia* treated; PR: prednisolone treated.

Control was taken as 100%

^aSignificantly different from the respective control value $P < 0.05$

^bSignificantly different from the respective UC control value $P < 0.05$




Figure 3: A typical association network of IL-1 β , IL-6, IL-23, IFN- γ , TNF- α , NF- κ B, and CCL-17 in STRING. IL: interleukin; IFN- γ : interferon γ ; TNF: tumor necrosis factor α ; NF- κ B: nuclear factor kappa B

NF- κ B is a protein complex that controls transcription, cytokine production associated with immunity and inflammation and cell viability^[15,83]. It is found in almost all animal cell types and is involved in the regulation of cellular responses to many stimuli, such as stress.^[84,85] In the literature, experimental studies are emphasizing the importance of NF- κ B in the pathogenesis of IBD.^[86] Our results were in agreement with the literature, wherein an up-regulation of NF- κ B mRNA and protein levels in experimental colitis,^[86] whose mRNA levels were decreased to even lower than the untreated control level with *MCh* treatment.

Inflammation is the physiological response against infectious agents, which is also involved in the pathophysiology of many diseases.^[18,87] The inflammatory stimuli cause activation of NF- κ B signaling, and it acts as a transcription factor for different pro-inflammatory cytokines such as IL-1 β , IL-6, IL-8, IL-12, IL-23, TNF- α , and IFN- γ .^[18,88] Therefore, suppression of NF- κ B signaling would be one of the therapeutic approaches to alleviate inflammation. In our experiment, we administered *MCh* orally after induction of colitis with TNBS and evaluated the therapeutic effect of *MCh*. Experimental colitis model induced with TNBS caused the loss of body weight, histological changes of the colon, and finally, the change of the tissue mRNA and protein levels of inflammatory cytokines (IL-1 β , IL-6, IL-23, IFN- γ , TNF- α , and CCL-17). In conclusion, mRNA expressions, histological analyses and changes in protein levels of genes associated with the disease show that *MCh* exhibited the protective effect on TNBS-instigated ulcerative colitis by inhibiting inflammation via NF- κ B mediated inflammatory responses and this suppression

effect at least associated with the expression of some pro-inflammatory cytokines, including IL-1 β , IL-6, IL-23, IFN- γ , TNF- α , and CCL-17.

We have further analyzed the protein-protein interaction network of IL-1 β , IL-6, IL-23, IFN- γ , TNF- α , and CCL-17 (Figure 3).^[89] It was found that these proteins have more interactions among themselves and involved in cytokine and chemokine mediated signaling pathway as expected. On the other hand, functional annotations of these proteins interestingly yielded another pathway, namely regulation of calcidiol 1-monooxygenase activity. Five out of the seven proteins investigated here were found to be involved in positive regulation of calcidiol 1-monooxygenase. It is also called 25-hydroxyvitamin D₃ 1-alpha-hydroxylase or cytochrome P450 27B1 (CYP27B1) and involved in the synthesis of active vitamin D₃ [1 α ,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃)].^[90] It is known that 1,25(OH)₂D₃ inhibits the production of inflammatory cytokines.^[91,92] Studies have shown that induction of colonic CYP27B1, enhancing the local production of 1,25(OH)₂D₃, is a protective mechanism for colonic inflammation.^[93,94] Collectively, these data suggest that *MCh* may exert its anti-inflammatory action through inducing the production of 1,25(OH)₂D₃ so as to protect the mucosal barrier and decrease colonic inflammation though it might be an exaggerated inference but highly probable in the light of current literature. Further studies are required for a better understanding of the role of either CYP27B1 or 1,25(OH)₂D₃ in the pathogenesis of UC.

Our data presented here demonstrated compelling pieces of evidence that the *MCh* marmalade is an efficient alternative and complementary therapeutics for the treatment of ulcerative colitis by alleviating the inflammation in colonic tissues. It suppressed the inflammation induced by TNBS and ameliorated the tissue damage, which was positively reflected in the preservation of animals' body weight and lower histochemical scores along with a reduction in inflammatory cytokine/chemokine productions. Additionally, *MCh* marmalade effects were in many characteristics equivalent to those attained by the standard drug (PR) treatment.

CONCLUSION

In conclusion, *M. charantia* is an essential alternative therapeutic or prophylactic agent for ulcerative colitis due to its low cost and lack of side effects as well as its ease of use. However, it should be kept in mind that individual dose adjustment is essential, and further pharmacokinetics and pharmacodynamics investigations are required to prevent possible drug and diet interactions. Besides, further supportive evaluation is required to elucidate the exact

mechanism of *MCh* as an anti-inflammatory agent in the management of IBD.

Conflict of Interest

The authors declared that they have no conflict of interest.

Acknowledgements

This work was supported by a grant from The Scientific and Technological Research Council of Turkey (TUBITAK 216Z093).

REFERENCES

1. Strober W, Fuss JJ. Pro-inflammatory cytokines in the pathogenesis of IBD. *Gastroenterology* 2013; 140: 1756–67.
2. Kuhnen A. Genetic and environmental considerations for inflammatory bowel disease. *Surg. Clin. North Am* 2019; 99: 1197–207.
3. Flynn S, Eisenstein S. Inflammatory bowel disease presentation and diagnosis. *Surg. Clin. North Am* 2019; 99: 1051–62.
4. Satsangi J, Jewell DP, Rosenberg WM, Bell JI. Genetics of inflammatory bowel disease. *Gut* 1994; 35: 696–700.
5. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, *et al.* Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget* 2018; 9: 7204–28.
6. Itoh J, De la Motte C, Strong SA, Levine AD, Fiocchi C. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. *Gut* 2001; 49: 35–41.
7. Muzes G, Molnár B, Tulassay Z, Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. *World J Gastroenterol* 2012; 18: 5848–461.
8. Aggarwal BB. Signalling pathways of the TNF superfamily: A double-edged sword. *Nat Rev Immunol* 2003; 3: 745–56.
9. Sartor RB. Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis. *Nat. Clin. Pract. Gastroenterol Hepatol* 2006; 3: 390–407.
10. He J, Liang J, Zhu S, Zhao W, Zhang Y, Sun W. Protective effect of taurohyodeoxycholic acid from *Pulvis Felleis Suis* on trinitrobenzene sulfonic acid induced ulcerative colitis in mice. *Eur J Pharmacol* 2011; 670: 229–35.
11. Motavallian A, Minaiyan M, Rabbani M, Mahzouni P, Andalib S, Abed A, *et al.* Does cisapride, as a 5HT₄ receptor agonist, aggravate the severity of TNBS-induced colitis in rat? *Gastroenterol Res Pract* 2012; 362536.
12. Motaghi E, Hajhashemi V, Mahzouni P, Minaiyan M. The effect of mepantidine on trinitrobenzene sulfonic acid-induced ulcerative colitis in mice. *Eur J Pharmacol* 2016; 793: 28–34.
13. Heiseke AF, Faul AC, Lehr H, Förster I, Schmid RM, Krug AB, *et al.* CCL17 promotes intestinal inflammation in mice and counteracts regulatory T cell-mediated protection from colitis. *Gastroenterology* 2012; 142: 335–45.
14. Ritter M, Göggel R, Chaudhary N, Wiedenmann A, Jung B, Weith A, *et al.* Elevated expression of TARC (CCL17) and MDC (CCL22) in models of cigarette smoke-induced pulmonary inflammation. *Biochem. Biophys. Res Commun* 2005; 334: 254–62.
15. Blackwell TS, Christman JW. The role of nuclear factor- κ B in cytokine gene regulation. *Am J Respir Cell Mol Biol* 1997; 17: 3–9.
16. Chen T, Guo ZP, Jiao XY, Jia RZ, Zhang YH, Li JY, *et al.* Peoniflorin suppresses tumor necrosis factor- α induced chemokine production in human dermal microvascular endothelial cells by blocking nuclear factor- κ B and ERK pathway. *Arch Dermatol Res* 2011; 303: 351–60.
17. Bhattacharjee N, Barma S, Konwar N, Dewanjee S, Manna P. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update. *Eur J Pharmacol* 2016; 791: 8–24.
18. Gu P, Zhu L, Liu Y, Zhang L, Liu J, Shen H. Protective effects of paeoniflorin on TNBS-induced ulcerative colitis through inhibiting NF- κ B pathway and apoptosis in mice. *Int Immunopharmacol* 2017; 50: 152–60.
19. Yun J, Xu C-T, Pan B-R. Epidemiology and gene markers of ulcerative colitis in the Chinese. *World J Gastroenterol* 2009; 15: 788.
20. Agus HH, Tekin P, Bayav M, Semiz A, Sen A. Drug interaction potential of the seed extract of *Urtica urens* L. (dwarf nettle). *Phyther Res* 2009; 23: 1763–70.
21. Suluvoy JK, Sakhivel KM, Guruvayoorappan GC, Berlin BG. Protective effect of *Averrhoa bilimbi* L. fruit extract on ulcerative colitis in wistar rats via regulation of inflammatory mediators and cytokines. *Biomed Pharmacother* 2017; 91: 1113–21.
22. Gürlek Kisacik Ö, Güneş Ü, Yaprakçı MV, Altunbaş K. Effectiveness of bitter melon extract in the treatment of ischemic wounds in rat. *Turkish J Biol* 2018; 42: 506–16.
23. Chao CY, Sung PJ, Wang WH, Kuo YH. Anti-inflammatory effect of *Momordica charantia* in sepsis mice. *Molecules* 2014; 19: 12777–88.
24. Gürbüz I, Akyüz Ç, Yeşilada E, Şener B. Anti-ulcerogenic effect of *Momordica charantia* L. fruits on various ulcer models in rats. *J Ethnopharmacol* 2000; 71: 77–82.
25. Scartezzini P, Speroni E. Review on some plants of Indian traditional medicine with antioxidant activity. *J Ethnopharmacol* 2000; 71: 23–43.
26. Beloin N, Gbeassor M, Akpagana K, Hudson J, de Souza K, Koumaglo K, *et al.* Ethnomedicinal uses of *Momordica charantia* (Cucurbitaceae) in Togo and relation to its phytochemistry and biological activity. *J Ethnopharmacol* 2005; 96: 49–55.
27. Cipriani TR, Mellinger CG, de Souza LM, Baggio CH, Freitas CS, Marques MCA, *et al.* A polysaccharide from a tea (Infusion) of *Maytenus ilicifolia* leaves with anti-ulcer protective effects. *J Nat Prod* 2006; 69: 1018–21.
28. Semiz A, Sen A. Antioxidant and chemoprotective properties of *Momordica charantia* L. (bitter melon) fruit extract. *African J Biotechnol* 2007; 6: 273–7.
29. Kumar KPS, Bhowmik D. Traditional medicinal uses and therapeutic benefits of *Momordica charantia* Linn. *Int J Pharm Sci Rev Res* 2010; 4: 23–8.
30. Ullah M, Chy FK, Sarkar SK, Islam MK, Absar N. Nutrient and phytochemical analysis of four varieties of bitter melon (*Momordica charantia*) grown in chittagong hill tracts, Bangladesh. *Asian J Agric Res* 2011; 5: 186–93.
31. Yeşilada E, Gürbüz I, Shibata H. Screening of Turkish anti-ulcerogenic folk remedies for anti-*Helicobacter pylori* activity. *J Ethnopharmacol* 1999; 66: 289–93.
32. El-Salhy M, Wendelbo IH, Gundersen D, Hatlebakk JG, Hausken T. Evaluation of the usefulness of colonoscopy with mucosal biopsies in the follow-up of TNBS-induced colitis in rats. *Mol Med Rep* 2013; 8: 446–50.
33. Ozgun-Acar O, Celik-Turgut G, Gazioglu I, Kolak U, Ozbal S, Ergur BU, *et al.* *Capparis ovata* treatment suppresses inflammatory cytokine expression and ameliorates experimental allergic encephalomyelitis model of multiple sclerosis in C57BL/6 mice. *J Neuroimmunol* 2016; 298: 106–16.
34. Luo S, Wen R, Wang Q, Zhao Z, Nong F, Fu Y, *et al.* Rhubarb Peony Decoction ameliorates ulcerative colitis in mice by regulating gut microbiota to restoring Th17/Treg balance. *J Ethnopharmacol* 2019; 231: 39–49.
35. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. *Am J Clin Pathol* 1957; 28: 56–63.
36. Wroblewski F, Ladue JS. Lactic dehydrogenase activity in blood. *Proc Soc Exp Biol Med* 1955; 90: 210–3.
37. Sen A, Ayar B, Yilmaz A, Ozgun-Acar O, Celik-Turgut G, Topçu G. Natural diterpenoid alysin A isolated from *Teucrium alyssifolium* exerts antidiabetic effect via enhanced glucose uptake and suppressed glucose absorption. *Turkish J Chem* 2019; 43: 1350–64.
38. Yavuz S, Cetin A, Akdemir A, Doyduk D, Disli A, Celik-Turgut G, *et al.* Synthesis and functional investigations of computer designed novel

- cladribine-like compounds for the treatment of multiple sclerosis. Arch. Pharm (Weinheim) 2017; 350: 201700185.
39. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, *et al.* Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985; 150: 76–85.
 40. Sen A, Arinc E. Purification and characterization of cytochrome P450 reductase from liver microsomes of feral laping mullet (*Liza saliens*). J Biochem Mol Toxicol 1998; 12: 103–13.
 41. Sen A, Arinc E. Further immunochemical and biocatalytic characterization of CYP1A1 from feral leaping mullet liver (*Liza saliens*) microsomes. Comp Biochem Physiol - C Pharmacol Toxicol Endocrinol 2000; 126: 235–44.
 42. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–5.
 43. Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front Neurol 2014; 177: 2013.00177.
 44. Neurath BMF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996; 183: 2605–16.
 45. Stallmach A, Wittig B, Giese T, Pfister K, Hoffmann JC, Bulfone-Paus S, *et al.* Protection of trinitrobenzene sulfonic acid-induced colitis by an interleukin 2-IgG2b fusion protein in mice. Gastroenterology 1999; 117: 866–76.
 46. Bliss DZ, Sawchuk L. Nursing management: Lower gastrointestinal problems. In: Medical surgical nursing, Lewis SM, Heitkemper MM, and Dirksen SR (eds.). 5th ed. Mosby 1999; pp. 1136–90.
 47. Antoniou E, Margonis GA, Angelou A, Pikouli A, Argiri P, Karavokyros I, *et al.* The TNBS-induced colitis animal model: An overview. Ann Med Surg 2016; 11: 9–15.
 48. Zimmerman HJ. Experimental Hepatotoxicity. In: Experimental Production of Diseases. Springer Berlin Heidelberg; 1976; 1–120.
 49. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: A guide for clinicians. Cmaj 2005; 172: 367–79.
 50. Celik G, Semiz A, Karakurt S, Arslan S, Adali O, Sen A. A comparative study for the evaluation of two doses of ellagic acid on hepatic drug metabolizing and antioxidant enzymes in the rat. Biomed Res Int 2013; 2013: 358945.
 51. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000; 164: 4878–82.
 52. Santiago C, Pagán B, Isidro AA, Appleyard CB. Prolonged chronic inflammation progresses to dysplasia in a novel rat model of colitis-associated colon cancer. Cancer Res 2007; 67: 10766–73.
 53. Okayasu I. Development of ulcerative colitis and its associated colorectal neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence. Pathol Int 2012; 62: 368–80.
 54. İlhan M, Bolat IE, Süntar I, Kutluay Köklü H, Uçar Çankal DA, Keleş H, *et al.* Topical application of olive oil macerate of *Momordica charantia* L. promotes healing of excisional and incisional wounds in rat buccal mucosa. Arch Oral Biol 2015; 60: 1708–13.
 55. Ozbakiş Dengiz G, Gürsan N. Effects of *Momordica charantia* L. (Cucurbitaceae) on indomethacin-induced ulcer model in rats. Turkish J Gastroenterol 2005; 16: 85–8.
 56. Raish M, Ahmad A, Ansari MA, Alkharfy KM, Aljanoobi FI, Jan BL, *et al.* *Momordica charantia* polysaccharides ameliorate oxidative stress, inflammation, and apoptosis in ethanol-induced gastritis in mucosa through NF- κ B signaling pathway inhibition. Int J Biol Macromol 2018; 111: 193–9.
 57. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect Biol 2014; 6: a016295.
 58. Lesina M, Wörmann SM, Neuhöfer P, Song L, Algül H. Interleukin-6 in inflammatory and malignant diseases of the pancreas. Semin Immunol 2014; 26: 80–7.
 59. Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer DL. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993; 104: 1285–92.
 60. Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein JS, *et al.*, Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993; 104: 749–58.
 61. Rachmilewitz D, Simon PL, Schwartz LW, Griswold DE, Fondacaro JD, Wasserman MA. Inflammatory mediators of experimental colitis in rats. Gastroenterology 1989; 97: 326–37.
 62. Ligumsky M. Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease. Gut 1990; 31: 686–9.
 63. Yang M, Lin HB, Gong S, Chen PY, Geng LL, Zeng YM, *et al.* Effect of Astragalus polysaccharides on expression of TNF- α , IL-1 β and NFATc4 in a rat model of experimental colitis. Cytokine 2014; 70: 81–6.
 64. Funakoshi K, Sugimura K, Anezaki K, Bannai H, Ishizuka K, Asakura H. Spectrum of cytokine gene expression in intestinal mucosal lesions of Crohn's disease and ulcerative colitis. Digestion 1998; 59: 73–8.
 65. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection : causes and consequences. J Pathol 2008; 214: 231–41.
 66. Mouzaoui S, Djerdjouri B, Makhezzi N, Krovianski Y, El-Benna J, Dang PMC. Tumor necrosis factor- α -induced colitis increases NADPH oxidase 1 expression, oxidative stress, and neutrophil recruitment in the colon: Preventive effect of apocynin. Mediators Inflamm 2014; 2014: 312484.
 67. Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P, *et al.* Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF- α , NF- κ Bp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm 2006; 2006: 92642.
 68. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066–78.
 69. Iwakura Y, Ishigame H. The IL-23 / IL-17 axis in inflammation. J Clin Invest 2006; 116: 1218–22.
 70. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, *et al.* Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715–25.
 71. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, *et al.*, IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233–40.
 72. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009; 15: 199–207.
 73. Kullberg MC, Jankovic D, Feng CG, Hue S, Gorelick PL, McKenzie BS, *et al.* IL-23 plays a key role in *Helicobacter hepaticus*-induced T cell-dependent colitis. J Exp Med 2006; 203: 2485–94.
 74. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, *et al.* IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin Invest 2006; 116: 1310–6.
 75. Yu LZ, Wang HY, Yang SP, Yuan ZP, Xu FY, Sun C, *et al.* Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. World J Gastroenterol 2013; 19: 2638–49.
 76. Sartor R. Cytokine regulation of experimental intestinal inflammation in genetically engineered and T-lymphocyte reconstituted rodents. Aliment Pharmacol Ther 1996; 10: 36–42.
 77. Simpson SJ, Shah S, Comiskey M, De Jong YP, Wang B, Mizoguchi E, *et al.* T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon γ expression by T cells. J Exp Med 1998; 187: 1225–34.
 78. Boyaka PN. Inducing mucosal IgA: A challenge for vaccine adjuvants and delivery systems. J Immunol 2017; 199: 9–16.
 79. Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer Zum Büschenfelde KH, *et al.* Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997; 27: 1743–50.

80. Sokol CL, Luster AD. The chemokine system in innate immunity. *Cold Spring Harb Perspect Biol* 2015; 7: 1–20.
81. Homey B, Meller S, Savinko T, Alenius H, Lauerma A. Modulation of chemokines by Staphylococcal superantigen in atopic dermatitis. *Chem. Immunol. Allergy* 2007; 93: 181–94.
82. Kristensen NN, Brudzewsky D, Gad M, Claesson MH. Chemokines involved in protection from colitis by CD4+CD25+ regulatory T cells. *Inflamm. Bowel Dis* 2006; 12: 612–8.
83. Gilmore TD. Introduction to NF- κ B: Players, pathways, perspectives. *Oncogene* 2006; 25: 6680–4.
84. Luqman S, Pezzuto JM. NF κ B: A promising target for natural products in cancer chemoprevention. *Phyther Res* 2010; 24: 949–63.
85. Liu T, Zhang L, Joo D, Sun SC. NF- κ B signaling in inflammation. *Signal Transduct Target Ther* 2017; 2: 17023
86. García-Mediavilla V, Crespo I, Collado PS, Esteller A, Sánchez-Campos S, Tuñón MJ, *et al.* The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. *Eur J Pharmacol* 2007; 557: 221–9.
87. Azab A, Nassar A, Azab AN. Anti-inflammatory activity of natural products. *Molecules* 2016; 21: 1–19.
88. Chen T, Mou Y, Tan J, Wei L, Qiao Y, Wei T, *et al.* The protective effect of CDDO-Me on lipopolysaccharide-induced acute lung injury in mice. *Int Immunopharmacol* 2015; 25: 55–64.
89. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, *et al.* STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* 2019; 47: D607–13.
90. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. *Trends Biochem Sci* 2004; 29: 664–73.
91. Verstuyf A, Carmeliet G, Bouillon R, Mathieu C. Vitamin D. A pleiotropic hormone. *Kidney Int* 2010; 78: 140–5.
92. Aranow C. Vitamin D and the immune system. *J Invest Med* 2011; 59: 881–6.
93. Du J, Wei X, Ge X, Chen Y, Li YC. Microbiota-dependent induction of colonic Cyp27b1 is associated with colonic inflammation: Implications of locally produced 1,25-Dihydroxyvitamin D3 in inflammatory regulation in the colon. *Endocrinology* 2017; 158: 4064–75.
94. Sen A, Stark H. Role of cytochrome P450 polymorphisms and functions in development of ulcerative colitis. *World J Gastroenterol* 2019; 25: 2846–62.

How to cite this article: Semiz A, Acar OO, Cetin H, Semiz G, Sen A. Suppression of inflammatory cytokines expression with bitter melon (*Momordica charantia*) in TNBS-instigated ulcerative colitis. *J Transl Intern Med* 2020; 8: 177-87.